EAGLE PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.47 USD | +1.31% |
|
-7.22% | -33.65% |
| May. 15 | Eagle Pharmaceuticals, Inc. Enters into a Third Amendment to Third Amended and Restated Credit Agreement | CI |
| May. 06 | North American Morning Briefing : Stock Futures -2- | DJ |
Presenter SpeechScott Tarriff (Executives)Good morning, everyone. Thank you for joining us, bo...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Eagle Pharmaceuticals, Inc. is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial capabilities. The Company is focused on developing medicines that result in improvements in patients' lives. The Company's commercialized products include vasopressin, PEMFEXY, RYANODEX, BENDEKA, BELRAPZO, TREAKISYM (Japan), and BYFAVO and BARHEMSYS through its wholly owned subsidiary Acacia Pharma Inc. Its oncology and central nervous system (CNS)/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. The Company also has a research and development facility in Cambridge, Massachusetts. The Company has office space in Palm Beach Gardens, Florida and Indianapolis, Indiana. The Companyâs subsidiaries include Eagle Biologics, Inc., Eagle Research Lab Limited, Acacia Pharma Group plc, Acacia Pharma Limited and Acacia Pharma Inc.
Sector
Pharmaceuticals
Calendar
2024-08-05
- Q2 2024 Earnings Release (Projected)
Related indices
| 1st Jan change | Capi. | |
|---|---|---|
| -33.65% | 45.06M | |
| +15.54% | 78.51B | |
| +12.87% | 9B | |
| +58.17% | 4.96B | |
| -14.94% | 4.84B | |
| -.--% | 3.72B | |
| -26.63% | 2.19B | |
| +16.75% | 2.12B | |
| -37.97% | 1.94B | |
| -0.50% | 1.64B |
- Stock Market
- Equities
- EGRX Stock
- News Eagle Pharmaceuticals, Inc.
- Transcript : Eagle Pharmaceuticals, Inc. - Analyst/Investor Day
